Case number 2018-2160
Celltrion, Inc. v. Genentech, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 30, 2018 | 50 | ORDER filed. The motions [49] [48] are granted. The above-captioned appeals are dismissed.; Each side shall bear its own costs.; ISSUED AS A MANDATE: November 30, 2018. Service: 11/30/2018 by clerk. [568857] [NL] [Entered: 11/30/2018 10:52 AM] (2) |
| Nov 27, 2018 | 49 | MOTION of Appellants Celltrion, Inc., Celltrion Healthcare Co., Ltd., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals International GmbH to voluntarily dismiss appeal pursuant to FRAP 42(b). [Consent: unopposed]. Service: 11/27/2018 by email. [567741] [18-2160] [Brian Burgess] [Entered: 11/27/2018 09:51 AM] (6) |
| Nov 2, 2018 | 48 | MOTION of Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc. to voluntarily dismiss appeal pursuant to FRAP 42(b). [Consent: unopposed]. Service: 11/02/2018 by email. [562277] [18-2160] [Brian Burgess] [Entered: 11/02/2018 02:06 PM] (10) |
| Oct 24, 2018 | 47 | ORDER granting motion to extend time to file brief [46] filed by Appellants Teva Pharmaceuticals USA, Inc., Celltrion Healthcare Co., Ltd., Celltrion, Inc. and Teva Pharmaceuticals International GmbH. No further extensions should be anticipated. Brief is due 11/28/2018. Service as of this date by the Clerk of Court. [559981] [JB] [Entered: 10/24/2018 11:36 AM] (2) |
| Oct 18, 2018 | 46 | MOTION of Appellants Celltrion, Inc., Celltrion Healthcare Co., Ltd., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals International GmbH to extend the time to 11/28/2018 to file the opening brief. [Consent: unopposed]. Service: 10/18/2018 by email. [558601] [18-2160] [Brian Burgess] [Entered: 10/18/2018 05:29 PM] (10) |
| Sep 25, 2018 | 45 | Corrected Entry of appearance for David I. Gindler as of counsel for Appellees Biogen Inc., City of Hope, Genentech, Inc. and Hoffmann-La Roche Inc.. Service: 09/25/2018 by email. [552566] [18-2160] [David Gindler] [Entered: 09/25/2018 07:06 PM] (2) |
| Sep 20, 2018 | 44 | Entry of appearance for David I. Gindler as of counsel for Appellees Genentech, Inc., Hoffmann-La Roche Inc. and City of Hope. Service: 09/20/2018 by email. [551512] [18-2160] [David Gindler] [Entered: 09/20/2018 04:49 PM] (3) |
| Sep 18, 2018 | 43 | NOTICE OF NON-COMPLIANCE: The submission of Appellees City of Hope, Genentech, Inc., and Hoffmann-La Roche Inc. in 18-2161, Entry of Appearance for David I. Gindler [548987-2], is not in compliance with the rules of this court (see attached). Compliant document due on 09/25/2018 in 18-2160. Service as of this date by the Clerk of Court. [550654] [18-2160, 18-2161] [MJL] [Entered: 09/18/2018 10:52 AM] (1) |
| Aug 30, 2018 | 42 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: Appellant's motion [39] did not contain the required certificate of compliance with the word count. CORRECTION: All motions require a certificate of compliance with FRAP 32(g)(1). Please ensure future motions contain a certificate of compliance. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [546387] [CMP] [Entered: 08/30/2018 11:55 AM] (0) |
| Aug 30, 2018 | 41 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a) and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [546383] [CMP] [Entered: 08/30/2018 11:53 AM] (0) |
| Aug 30, 2018 | 40 | **TEXT ONLY** ORDER granting motion to extend time to file brief [39] filed by Appellants Teva Pharmaceuticals USA, Inc., Celltrion Healthcare Co., Ltd., Celltrion, Inc. and Teva Pharmaceuticals International GmbH. Brief is due by 10/29/2018. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [546382] [CMP] [Entered: 08/30/2018 11:52 AM] (0) |
| Aug 27, 2018 | 39 | MOTION of Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc. to extend the time to 10/29/2018 to file the Appellants' opening brief. [Consent: unopposed]. Service: 08/27/2018 by email. [545709] [18-2160] [Brian Burgess] [Entered: 08/27/2018 05:43 PM] (9) |
| Aug 27, 2018 | 38 | Corrected Certificate of Interest for the Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 08/27/2018 by email. [545707] [18-2160] [Brian Burgess] [Entered: 08/27/2018 05:39 PM] (3) |
| Aug 2, 2018 | 37 | Entry of appearance for Michelle S. Rhyu as of counsel for Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/30/2018 by email. [540473] [18-2160] [Michelle Rhyu] [Entered: 08/02/2018 03:20 PM] (2) |
| Aug 1, 2018 | 36 | Corrected Entry of appearance for Kevin DeJong as of counsel for Appellant Celltrion, Inc.. Service: 08/01/2018 by email. [540084] [18-2160] [Kevin DeJong] [Entered: 08/01/2018 11:49 AM] (3) |
| Aug 1, 2018 | 35 | NOTICE OF DEFICIENCY: The attorney entry of appearance for Kevin DeJong [34] includes an incomplete name of party represented and therefore cannot be accepted for filing at this time. Please correct the name of party as necessary so that the docket entry text matches the name of party entered on the appearance. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [539928] [SJL] [Entered: 08/01/2018 08:47 AM] (0) |
| Jul 31, 2018 | 26 | Corrected Docketing Statement for the Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/31/2018 by email. [539682] [18-2160] [Brian Burgess] [Entered: 07/31/2018 11:20 AM] (3) |
| Jul 31, 2018 | 34 | Entry of appearance for Kevin DeJong as of counsel for Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/31/2018 by email. [539730] [18-2160] [Kevin DeJong] [Entered: 07/31/2018 01:09 PM] (0) |
| Jul 31, 2018 | 33 | Corrected Entry of appearance for Elaine Herrmann Blais as of counsel for Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/31/2018 by email. [539708] [18-2160] [Elaine Blais] [Entered: 07/31/2018 11:49 AM] (3) |
| Jul 31, 2018 | 32 | Corrected Entry of appearance for Robert V. Cerwinski as of counsel for Appellants Celltrion Healthcare Co., Ltd., Teva Pharmaceuticals International GmbH, Teva Pharmaceuticals USA, Inc. and Appellee City of Hope. Service: 07/31/2018 by email. [539703] [18-2160] [Robert Cerwinski] [Entered: 07/31/2018 11:40 AM] (3) |
| Jul 31, 2018 | 31 | Corrected Entry of appearance for Natasha E. Daughtrey as of counsel for Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/31/2018 by email. [539702] [18-2160] [Natasha Daughtrey] [Entered: 07/31/2018 11:38 AM] (3) |
| Jul 31, 2018 | 30 | Corrected Entry of appearance for Elizabeth J. Holland as of counsel for Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/31/2018 by email. [539700] [18-2160] [Elizabeth Holland] [Entered: 07/31/2018 11:35 AM] (3) |
| Jul 31, 2018 | 23 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [4], attorney entry of appearance Docket No. [5], ERROR: Name of party is incorrect. CORRECTION: For future filings please include the full and complete names of party represented. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [539573] [SJL] [Entered: 07/31/2018 08:39 AM] (0) |
| Jul 31, 2018 | 24 | NOTICE OF DEFICIENCY: The certificate of interest [20] , docketing statement [19] , and attorney entries of appearance [14] , [13] , [12] , [11] , [10] , [9] ,and [8] filed by Appellants Teva Pharmaceuticals USA, Inc., Celltrion Healthcare Co., Ltd., Celltrion, Inc. and Teva Pharmaceuticals International GmbH in 18-2160 are not signed and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [539586] [SJL] [Entered: 07/31/2018 09:05 AM] (0) |
| Jul 31, 2018 | 25 | Corrected Certificate of Interest for the Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/31/2018 by email. [539673] [18-2160] [Brian Burgess] [Entered: 07/31/2018 11:13 AM] (3) |
| Jul 31, 2018 | 29 | Corrected Entry of appearance for Daryl L. Wiesen as of counsel for Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/31/2018 by email. [539694] [18-2160] [Daryl Wiesen] [Entered: 07/31/2018 11:31 AM] (3) |
| Jul 31, 2018 | 27 | Corrected Entry of appearance for Brian Burgess as principal counsel for Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/31/2018 by email. [539687] [18-2160] [Brian Burgess] [Entered: 07/31/2018 11:24 AM] (3) |
| Jul 31, 2018 | 28 | Corrected Entry of appearance for Huiya Wu as of counsel for Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/31/2018 by email. [539691] [18-2160] [Huiya Wu] [Entered: 07/31/2018 11:29 AM] (3) |
| Jul 30, 2018 | 17 | Entry of appearance for Cynthia Lambert Hardman as of counsel for Appellant Celltrion, Inc.. Service: 07/30/2018 by email. [539528] [18-2160] [Cynthia Hardman] [Entered: 07/30/2018 06:26 PM] (3) |
| Jul 30, 2018 | 22 | Entry of appearance for Eamonn Gardner as of counsel for Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/30/2018 by clerk, email. [539552] [18-2160] [Eamonn Gardner] [Entered: 07/30/2018 09:04 PM] (2) |
| Jul 30, 2018 | 21 | Certificate of Compliance with Fed. R. App. P. 10(b) [The Transcript of Proceedings] for Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/30/2018 by email. [539537] [18-2160] [Brian Burgess] [Entered: 07/30/2018 07:04 PM] (5) |
| Jul 30, 2018 | 20 | Corrected Certificate of Interest for the Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/30/2018 by email. [539535] [18-2160] [Brian Burgess] [Entered: 07/30/2018 06:56 PM] (0) |
| Jul 30, 2018 | 19 | Docketing Statement for the Appellants Celltrion, Inc., Celltrion Healthcare Co., Ltd., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals International GmbH. Service: 07/30/2018 by email. [539533] [18-2160] [Brian Burgess] [Entered: 07/30/2018 06:51 PM] (0) |
| Jul 30, 2018 | 18 | Certificate of Interest for the Appellants Celltrion, Inc., Celltrion Healthcare Co., Ltd., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals International GmbH. Service: 07/30/2018 by email. [539532] [18-2160] [Brian Burgess] [Entered: 07/30/2018 06:44 PM] (4) |
| Jul 30, 2018 | 16 | Entry of appearance for Neel Chatterjee as of counsel for Appellant Celltrion, Inc.. Service: 07/30/2018 by email. [539526] [18-2160] [Indra Chatterjee] [Entered: 07/30/2018 06:08 PM] (3) |
| Jul 30, 2018 | 15 | Entry of appearance for Brett M. Schuman as of counsel for Appellant Celltrion, Inc.. Service: 07/30/2018 by email. [539523] [18-2160] [Brett Schuman] [Entered: 07/30/2018 05:53 PM] (3) |
| Jul 30, 2018 | 14 | Entry of appearance for Elaine Herrmann Blais as of counsel for Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/30/2018 by email. [539521] [18-2160] [Elaine Blais] [Entered: 07/30/2018 05:46 PM] (0) |
| Jul 30, 2018 | 13 | Entry of appearance for Brian Burgess as principal counsel for Appellants Celltrion, Inc., Celltrion Healthcare Co., Ltd., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/30/2018 by email. [539520] [18-2160] [Brian Burgess] [Entered: 07/30/2018 05:43 PM] (0) |
| Jul 30, 2018 | 12 | Entry of appearance for Robert V. Cerwinski as of counsel for Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/30/2018 by email. [539519] [18-2160] [Robert Cerwinski] [Entered: 07/30/2018 05:39 PM] (0) |
| Jul 30, 2018 | 11 | Entry of appearance for Elizabeth J. Holland as of counsel for Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/30/2018 by email. [539512] [18-2160] [Elizabeth Holland] [Entered: 07/30/2018 05:17 PM] (0) |
| Jul 30, 2018 | 10 | Entry of appearance for Natasha E. Daughtrey as of counsel for Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/30/2018 by email. [539510] [18-2160] [Natasha Daughtrey] [Entered: 07/30/2018 05:11 PM] (0) |
| Jul 30, 2018 | 9 | Entry of appearance for Daryl L. Wiesen as of counsel for Appellants Celltrion Healthcare Co., Ltd., Celltrion, Inc., Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/30/2018 by email. [539493] [18-2160] [Daryl Wiesen] [Entered: 07/30/2018 04:44 PM] (0) |
| Jul 30, 2018 | 8 | Entry of appearance for Huiya Wu as of counsel for Appellants Celltrion, Inc., Celltrion Healthcare Co., Ltd., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals International GmbH. Service: 07/30/2018 by email. [539491] [18-2160] [Huiya Wu] [Entered: 07/30/2018 04:39 PM] (0) |
| Jul 30, 2018 | 7 | Docketing Statement for the Appellees Genentech, Inc., Biogen Inc., Hoffmann-La Roche Inc. and City of Hope. Service: 07/30/2018 by email, US mail. [539452] [18-2160] [Nicholas Groombridge] [Entered: 07/30/2018 03:30 PM] (5) |
| Jul 30, 2018 | 6 | Certificate of Interest for the Appellees Genentech, Inc., Biogen Inc., Hoffmann-La Roche Inc. and City of Hope. Service: 07/30/2018 by email, US mail. [539451] [18-2160] [Nicholas Groombridge] [Entered: 07/30/2018 03:28 PM] (4) |
| Jul 30, 2018 | 5 | Entry of appearance for Jennifer H. Wu as of counsel for Appellees Genentech, Inc., Biogen Inc., Hoffmann-La Roche Inc. and City of Hope. Service: 07/30/2018 by email, US mail. [539450] [18-2160] [Nicholas Groombridge] [Entered: 07/30/2018 03:26 PM] (2) |
| Jul 30, 2018 | 4 | Entry of appearance for Nicholas Groombridge as principal counsel for Appellees Genentech, Inc., Biogen Inc., Hoffmann-La Roche Inc. and City of Hope. Service: 07/30/2018 by email, US mail. [539448] [18-2160] [Nicholas Groombridge] [Entered: 07/30/2018 03:23 PM] (2) |
| Jul 25, 2018 | 3 | Note to file: The following cases are associated: 18-2160 Lead with 18-2161 Consolidated. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [538573] [18-2160, 18-2161] [CMP] [Entered: 07/25/2018 05:21 PM] (0) |
| Jul 23, 2018 | 2 | ORDER consolidating appeals (18-2160, 18-2161). The revised official caption is reflected in the order. The appellants opening brief is due no later than September 14, 2018. Service as of this date by the Clerk of Court. [538572] [18-2160, 18-2161] [CMP] [Entered: 07/25/2018 05:12 PM] (2) |
| Jul 16, 2018 | 1 | Appeal docketed. Received: 07/12/2018. [535972]Entry of Appearance due 07/30/2018. Certificate of Interest is due on 07/30/2018. Docketing Statement due 07/30/2018. Appellant's brief is due 09/14/2018. [CMP] [Entered: 07/16/2018 08:52 AM] (50) |
